| Eligible to autologous stem-cell transplantation (first line treatment) |
| CyBorD (cyclophosphamide + bortezomib + dexamethasone) |
|
| Lenalidomide + dexamethasone |
|
| VTD (bortezomib + thalidomide + dexamethasone) |
|
| Lenalidomide maintenance therapy after autologous stem cell transplant |
|
| Transplant-ineligible patients (first line treatment) |
| Daratumumab + lenalidomide + dexamethasone |
|
| Lenalidomide + dexamethasone |
|
| CyBorD (cyclophosphamide + bortezomib + dexamethasone) |
|
| Daratumumab + VMP (bortezomib + melphalan + prednisone) |
|
| VMP (bortezomib + melphalan + prednisone) |
|
| VTD (bortezomib + thalidomide + dexamethasone) |
|
| Bortezomib + dexamethasone |
|
| Relapse/refractory (2nd line and more) |
| KRd (carfilzomib + lenalidomide + dexamethasone) (2nd to 4th line) |
|
| Kd (carfilzomib + dexamethasone) (2nd to 4th line) |
|
| Lenalidomide + dexamethasone |
|
| DRd (daratumumab + lenalidomide + dexamethasone) |
|
| DVd (daratumumab + bortezomib + dexamethasone) |
|
| IRd (ixazomib + lenalidomide + dexamethasone) (2nd to 4th line) |
|
| Pomalidomide + dexamethasone (3rd line and more) |
|
Groupe d'étude en oncologie du Québec